Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Novartis Venture Fund

Founders Argeris Karabelas

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 255
Average round size
info
The average size of a deal this fund participated in
$31M
Portfolio companies 142
Rounds per year 9.11
Lead investments 48
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.44
Exits 59
Key employees 5
Stages of investment
Early Stage Venture
Late Stage Venture
Seed

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

In 1996 was created Novartis Venture Fund, which is appeared as VC. The main department of described VC is located in the Basel. The fund was located in Europe if to be more exact in Switzerland. Novartis Venture Fund appeared to be a CVC structure as part of the corporation.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Novartis Venture Fund, startups are often financed by SV Health Investors, Apple Tree Partners, ARCH Venture Partners. The meaningful sponsors for the fund in investment in the same round are Versant Ventures, Venture Investors, Truffle Capital. In the next rounds fund is usually obtained by Sofinnova Investments, Astellas Venture Management, Venture Investors.

For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Medical Device, Life Science. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Alios BioPharma, Merus, Catalyst Biosciences The fund has exact preference in some founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little.

The fund was created by Argeris Karabelas. The overall number of key employees were 5.

The fund is constantly included in 7-12 deals per year. The usual things for fund are deals in the range of 10 - 50 millions dollars. This Novartis Venture Fund works on 4 percentage points less the average amount of lead investments comparing to the other organizations. The higher amount of exits for fund were in 2014. The high activity for fund was in 2009. Despite it in 2019 the fund had an activity. The real fund results show that this VC is 7 percentage points more often commits exit comparing to other companies. When the investment is from Novartis Venture Fund the average startup value is 10-50 millions dollars.

Read more

Funds with similar focus

Funds from Switzerland
Funds with similar focus located in Switzerland:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Enterprise Therapeutics

Health Care
Health Diagnostics
Therapeutics
$35M29 Jan 2024 United Kingdom, England, United Kingdom

Aravax

Biotechnology
Health Care
Wellness
$22M23 Jan 2024 Melbourne, Victoria, Australia

AstronauTx

Pharmaceutical
$65M08 Oct 2023 United Kingdom, England, United Kingdom

Hyku

Biopharma
Biotechnology
Life Science
$56M19 Sep 2023 Lexington, Kentucky, United States

Hepalink

Manufacturing
Semiconductor
07 Sep 2023 Yangzhou, Jiangsu, China

Tagworks Pharmaceuticals

Biotechnology
Health Care
Medical
Pharmaceutical
$65M22 Jun 2023 Nijmegen, Gelderland, The Netherlands

Mediar Therapeutics

Biotechnology
Therapeutics
$85M15 Mar 2023 Cambridge, Massachusetts, United States

Catalym

Therapeutics
$59M22 Nov 2022 Munich, Bavaria, Germany

Capstan Therapeutics

Biotechnology
Health Care
Therapeutics
$102M14 Sep 2022 San Diego, California, United States
News
Immunitas Therapeutics Closes $58M in Series B Financing

– Immunitas Therapeutics, a Waltham, MA-based single cell genomics-based therapeutics company, closed a $58m Series B financing.
– The round was led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment, The Mark Foundation for Cancer Research, NS Investment, BrightEdge (American Cancer Society), and The Leukemia & Lymphoma Society . Existing investors Alexandria Venture Investments, Evotec, Leaps by Bayer, M Ventures, Novartis Venture Fund (NVF), and founding investor Longwood Fund also joined the round.
– The company intends to use the funds to advance its lead program, IMT-009, a CD161 inhibitor, into the clinic to treat both solid tumors and hematological malignancies.

GentiBio Raises $157M in Series A Financing

– GentiBio, Inc. from Boston develops engineered regulatory T cells (Tregs) therapies for immunology.
– Series A $157m round was led by Matrix Capital Management with participation from Avidity Partners, JDRF T1D Fund, OrbiMed, RA Capital Management, and Novartis Venture Fund.
– The company intends to use the funds to advance its potential functional cure for Type 1 Diabetes (T1D) to the clinic alongside multiple other pipeline programs in chronic autoimmunity and autoinflammation.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Novartis Venture Fund?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 255
Average round size 31M
Rounds per year 9.11
Peak activity year 2009
Lead investments 48
Follow on index 0.44
Exits 59
Group Appearance index 0.99

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Enterprise Therapeutics

Health Care
Health Diagnostics
Therapeutics
$35M29 Jan 2024 United Kingdom, England, United Kingdom

Aravax

Biotechnology
Health Care
Wellness
$22M23 Jan 2024 Melbourne, Victoria, Australia

AstronauTx

Pharmaceutical
$65M08 Oct 2023 United Kingdom, England, United Kingdom

Hyku

Biopharma
Biotechnology
Life Science
$56M19 Sep 2023 Lexington, Kentucky, United States

Hepalink

Manufacturing
Semiconductor
07 Sep 2023 Yangzhou, Jiangsu, China

Tagworks Pharmaceuticals

Biotechnology
Health Care
Medical
Pharmaceutical
$65M22 Jun 2023 Nijmegen, Gelderland, The Netherlands

Mediar Therapeutics

Biotechnology
Therapeutics
$85M15 Mar 2023 Cambridge, Massachusetts, United States

Catalym

Therapeutics
$59M22 Nov 2022 Munich, Bavaria, Germany

Capstan Therapeutics

Biotechnology
Health Care
Therapeutics
$102M14 Sep 2022 San Diego, California, United States
Crunchbase icon

Content report

The following text will be sent to our editors: